Notably, SOX2, which can reprogram differentiated glioma cells to glioma stem-like cells (GSCs), has been identified as a bona fide m6A target of METTL3 (19), but the downstream m6A reader of SOX2 in GBM remains unknown. Here, METTL3 is linked to central nervous system cancer.